You are here:

oxycodone / naloxone (Targinact)

Advice

Following a full submission

oxycodone/naloxone prolonged release tablets (Targinact) are not recommended for use within NHS Scotland for the treatment of severe pain which can be adequately managed only with opioid analgesics.

The addition of naloxone to oxycodone did not impair analgesia and improved bowel function when patients were not receiving regular laxative therapy. However the clinical benefit in patients receiving regular laxative therapy is uncertain and the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Drug Details

Drug Name: oxycodone / naloxone (Targinact)
SMC Drug ID: 541/09
Manufacturer: Napp Pharmaceuticals Ltd
Indication: Severe pain which can be adequately managed only with opioid analgesics. Naloxone is added to counteract opioid-induced constipation.
BNF Category:
Sub Category: 4.7 Analgesics
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 9 March 2009

Back